Jacobson represents clients across the pharmaceutical, biotech, medical device, and consumer products sectors on a broad range of regulatory, compliance and contentious matters. She advises multinational companies on navigating complex regulatory frameworks and managing risk across multiple jurisdictions and represents them in complex litigation, including product liability disputes, regulatory enforcement actions, investigations, coronial inquests and class action defense. She is recognized in both Chambers and Legal 500.

Jacobson is the latest addition to King & Spalding’s Sydney office, which launched in October 2025 to serve as gateway to the firm’s integrated cross-practice capabilities around the globe for multinational clients doing business in the Asia-Pacific region.

“Mandi’s deep experience adds to our strength in covering complex regulatory investigations and commercial disputes for our multinational clients,” said Darren Gardner, managing partner of the Sydney office. “In particular, Mandi’s life sciences credentials build on our strategy of expanding our core areas of focus in the Sydney office, supplementing our technology, energy, disputes, life sciences and global human capital capabilities.”

“King & Spalding offers a truly distinctive platform in Australia. The firm’s focus on providing U.S. and international clients with the best on-the-ground lawyers for their most sophisticated legal issues, as well as direct access to market-leading regulatory, litigation and transactional capabilities around the world, is an incredibly attractive proposition for me and my practice,” Jacobson added. “The is complemented by the firm’s wider Asia-Pacific footprint and ever-growing international platform, making King & Spalding a natural destination for me.”